GNSC Genaissance Pharmaceuticals (MM)

Genaissance Pharmaceuticals to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference NEW HAVEN, Conn., April 27 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals, will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference in Paris, France, at 3:30 p.m. local time (9:30 a.m. Eastern) on Wednesday, May 4, 2005. Mr. Rakin's remarks will also be available via a live webcast that can be accessed through the Company's website: http://www.genaissance.com/. Genaissance Pharmaceuticals, Inc. is developing innovative products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. Genaissance also markets its proprietary FAMILION(TM) Test, designed to detect mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. The Company's product development strategy is focused on drug candidates with promising clinical profiles and finding genetic markers to identify a responsive patient population. This strategy is designed to enable Genaissance to leverage existing clinical data and, thus, reduce the costs and risks associated with traditional drug development and increase the probability of clinical success and commercialization. The Company's lead therapeutic product, vilazodone for depression, is in Phase II of development. For more information on Genaissance, visit the Company's website at: http://www.genaissance.com/. DATASOURCE: Genaissance Pharmaceuticals, Inc. CONTACT: Kevin Rakin, President & Chief Executive Officer, Genaissance Pharmaceuticals, Inc., +1-203-773-1450; or Rhonda Chiger (investors), Rx Communications Group, +1-917-322-2569; or Tom Redington (media), Redington, Inc., +1-203-222-7399 Web site: http://www.genaissance.com/

Copyright